Dimerix acquired Mission Therapeutics’ acute kidney injury candidate in a deal structured with an upfront payment plus milestone funding. Dimerix will pay $5 million upfront and commit to as much as $287 million in milestones for Mission’s Phase 2-ready program, according to the transaction update. The announcement also notes that Mission appears to be winding down, reflecting how late-stage rescue assets can become scarce when pipelines stall. For Dimerix, the purchase adds a near-term development candidate in a high-need area where successful AKI therapies have historically struggled to reach approval. The structure suggests Dimerix is sharing risk on efficacy and development execution with milestone payments, while securing a program positioned for earlier clinical progression than a discovery-stage asset. In today’s M&A environment, the deal is a clear example of capital reallocations toward assets with defined clinical readiness and regulatory momentum rather than platform-only bets.